Growth Differentiation Factor-15 Levels at Admission Provide Incremental Prognostic Information on All-Cause Long-term Mortality in ST-Segment Elevation Myocardial Infarction Patients Treated with Primary Percutaneous Coronary Intervention.

GDF-15 Mortality NTproBNP Prognosis Risk stratification STEMI

Journal

Cardiology and therapy
ISSN: 2193-8261
Titre abrégé: Cardiol Ther
Pays: England
ID NLM: 101634495

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 02 12 2018
pubmed: 1 2 2019
medline: 1 2 2019
entrez: 1 2 2019
Statut: ppublish

Résumé

To investigate the additive prognostic value of growth differentiation factor (GDF-15) levels in ST-segment elevation myocardial infarction (STEMI) patients treated with primary percutaneously coronary intervention (pPCI) with 10-year mortality on top of clinical characteristics and known cardiac biomarkers. Baseline serum GDF-15 levels were measured in 290 STEMI patients treated with pPCI in the MISSION! intervention trial conducted from February 1, 2004 through October 31, 2006. The incremental prognostic value of GDF-15 and NTproBNP levels was evaluated on top of clinical characteristics using Cox proportional hazards analysis, Chi-square models and C-index. Outcome was 10-year all-cause mortality. Mean age was 59.0 ± 11.5 years and 65 (22.4) patients were female. A total of 37 patients died during a follow-up of 9.4 (IQR 8.8-10.0) years. Multivariable Cox regression revealed GDF-15 and NTproBNP levels above median to be independently associated with 10-year all-cause mortality [HR GDF-15, 2.453 (95% CI 1.064-5.658), P = 0.04; HR NTproBNP, 2.413 (95% CI 1.043-5.564), P = 0.04] after correction for other clinical variables. Stratified by median GDF-15 (37.78 pmol/L) and NTproBNP (11.74 pmol/L) levels, Kaplan-Meier curves showed significant better survival for patients with GDF-15 and NTproBNP levels below the median versus above the median. The likelihood ratio test showed a significant incremental value of GDF-15 (P = 0.03) as compared with a model with clinically important variables and NTproBNP. The C-statistics for this model improved from 0.82 to 0.84 when adding GDF-15. GDF-15 levels at admission in STEMI patients are independently associated with 10-year all-cause mortality rates and could improve risk stratification on top of clinical variables and other cardiac biomarkers.

Identifiants

pubmed: 30701401
doi: 10.1007/s40119-019-0127-4
pii: 10.1007/s40119-019-0127-4
pmc: PMC6525222
doi:

Types de publication

Journal Article

Langues

eng

Pagination

29-41

Références

Circulation. 2000 Oct 24;102(17):2031-7
pubmed: 11044416
Eur Heart J. 2003 Jan;24(1):28-66
pubmed: 12559937
Circulation. 2004 Aug 31;110(9):e82-292
pubmed: 15339869
Heart. 2006 Jun;92(6):735-40
pubmed: 16251228
Circ Res. 2006 Feb 17;98(3):351-60
pubmed: 16397141
Circ Res. 2006 Feb 17;98(3):342-50
pubmed: 16397142
Eur Heart J. 2006 Feb;27(4):419-26
pubmed: 16407373
Am Heart J. 2007 Jan;153(1):14.e1-11
pubmed: 17174628
Clin Chem. 2007 Feb;53(2):284-91
pubmed: 17185363
Circulation. 2007 Feb 27;115(8):962-71
pubmed: 17283261
J Am Coll Cardiol. 2008 Feb 12;51(6):618-26
pubmed: 18261680
Eur Heart J. 2009 May;30(9):1057-65
pubmed: 19168526
Eur Heart J. 2009 Oct;30(19):2346-53
pubmed: 19561023
Circ Cardiovasc Genet. 2010 Feb;3(1):88-96
pubmed: 20160200
Arterioscler Thromb Vasc Biol. 2011 Jan;31(1):203-10
pubmed: 20966402
Heart. 2011 Apr;97(8):632-40
pubmed: 21345844
Circulation. 2011 May 17;123(19):2101-10
pubmed: 21536998
Scand J Clin Lab Invest. 2012 Feb;72(1):45-51
pubmed: 22023041
JAMA. 2012 Sep 12;308(10):998-1006
pubmed: 22928184
Curr Heart Fail Rep. 2012 Dec;9(4):337-45
pubmed: 22961192
J Am Coll Cardiol. 2013 Mar 26;61(12):1222-30
pubmed: 23500325
Heart. 2014 Apr;100(7):582-9
pubmed: 24436220
J Am Coll Cardiol. 2014 Nov 18-25;64(20):2101-8
pubmed: 25457398
Am Heart J. 2015 Jun;169(6):879-889.e7
pubmed: 26027627
Eur Heart J. 2016 Apr 21;37(16):1325-33
pubmed: 26417057
Eur J Heart Fail. 2016 Jan;18(1):81-8
pubmed: 26497848
BMC Cardiovasc Disord. 2016 May 06;16:82
pubmed: 27154403
J Am Heart Assoc. 2016 May 20;5(5):
pubmed: 27207959
Clin Chim Acta. 2016 Sep 1;460:211-9
pubmed: 27374304
Ann Transl Med. 2016 Jul;4(13):258
pubmed: 27500159
Clin Chem. 2017 Feb;63(2):573-584
pubmed: 27932413
Curr Cardiol Rep. 2017 Apr;19(4):29
pubmed: 28315120
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
Eur Heart J. 2018 Jan 7;39(2):119-177
pubmed: 28886621
Stat Med. 1996 Feb 28;15(4):361-87
pubmed: 8668867
Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11514-9
pubmed: 9326641

Auteurs

Mathijs C Bodde (MC)

Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.

Maaike P J Hermans (MPJ)

Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.

Arnoud van der Laarse (A)

Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.
Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, The Netherlands.

Bart Mertens (B)

Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden, The Netherlands.

Fred P H T M Romijn (FPHTM)

Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, The Netherlands.

Martin J Schalij (MJ)

Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.

Christa M Cobbaert (CM)

Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, The Netherlands.

J Wouter Jukema (JW)

Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands. j.w.jukema@lumc.nl.

Classifications MeSH